Floatz logo

23me-00610

MSI-H Cancer

23andMe, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the MSI-H Cancer cohort.

Asset / SponsorPhaseRating
Tiragolumab
University Medical Center Groningen
Phase 2CCC
Atezolizumab
University Medical Center Groningen
Phase 2CCC
Decoy20
Indaptus Therapeutics, Inc
Phase 1/2CC
Pyrotinib
Indaptus Therapeutics, Inc
Phase 1/2CC
Mdna11
Medicenna Therapeutics, Inc.
Phase 1/2CC

View all 11 →

Same molecule, other indications

23me-00610 is also rated in:

Cancer With A High Tumor Mutational BurdenDormant
CCC
Indicative ·
48 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →